Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Oncology

Articles with lock require a GLG News subscription
Posted April 2, 2008
An unmet need still unmet, tough luck for Pfizer
Analysis of: Pfizer Ends Clinical Trial Of Melanoma Treatment | online.wsj.com
Author: GLG Member Program Contributor
Drug (monoclonal ab?) failed in a phase III trial vs chemotherapy (not particularly effective.)
Posted April 2, 2008
Hype and hope for another cancer vaccine
Analysis of: Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer | www.pipelinereview.com
Author: GLG Member Program Contributor
Biological efficacy has been shown for a number of cancer vaccines. Clinical efficacy has been shown in few of them. Clinical benefit just in one: idiotype vaccine for B-cell lymphoma. TroVax still has to clear the last hurdle, and likely also the second one.
Posted April 1, 2008
Amgen, Well at least they have Aranesp. (Whoops!)
Analysis of: Unexpected Toxicity with Panitumumab Plus Chemotherapy-Bevacizumab Combo in Colorectal Cancer | www.oncology-times.com
Author: GLG Member Program Contributor
Vectibix's undue toxicity without obvious benefits punctures Amgen's hope of finding a first or even second line use for this EGFR directed monoclonal antibody.
Posted April 1, 2008
Implications of mechanism's of action? Who cares if it works!
Analysis of: OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination with Bevacizumab and Chemotherapy | www.pipelinereview.com
Author: GLG Member Program Contributor
OXiGENE, Inc's., ZYBRESTAT(TM) (fosbretabulin), a vascular disrupting agent (?) is being given with Taxol/Carboplatin (T/C) in a randomized Phase II study. Soooo T/C with or without ZYBRESTAT.
Posted March 31, 2008
Well at least they have Procrit (Whoops!)
Analysis of: Cancer risk seen with J&J foot gel: FDA | uk.reuters.com
Author: GLG Member Program Contributor
 "A Johnson & Johnson foot gel used by diabetics may increase the risk of cancer and death, U.S. health officials said on Thursday in announcing an investigation into the issue."
Posted March 31, 2008
New Therapy for Hormone Refractory Prostate CA. Maybe!!!
Analysis of: Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer | www.pipelinereview.com
Author: GLG Member Program Contributor
Phase II results ++
Posted March 31, 2008
Immunoconjugates Are Better in Theory Than Practice
Analysis of: Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine Columbia University College of Physicians and Surgeons
Immunomedics has developed three new immunoconjugates between monoclonal antibodies and SN-38 i an effort to target colon, pancreas and lung cancer.  Preclinical data are effective in a metastatic colon cancer model but there are no clinical data.
Posted March 27, 2008
Innovative therapies for cancer by Immunomedics - a promising ttherapeutic intervention
Analysis of: Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers | www.pipelinereview.com
Author: GLG Member Program Contributor
The article published in the www.pipelinereview.com is presenting the clinical efficacy of three new antibody-drug conjugates aimed at treating pancreatic, colon, and lung cancers. The chemical compunds of each of these drugs are designed to treat specific cancer without posing a threat to normal...
Posted March 27, 2008
DNAi - early stage excitement
Analysis of: Pronai Therapeutics, Inc. cleared to begin Phase I clinical trials for the first DNA interference (DNAi (R)) therapeutic | www.pipelinereview.com
Author: GLG Member Program Contributor
DNAi technology, as presented by Pronal Therapeutics provides an exciting opportunity to use this technology as a therapeutic.  PNT2258 may be an important nucleic acid in combating certain types of cancer and solid tumor.  It is an important milestone to have FDA acceptance to begin Phase...
Posted March 27, 2008
New kind of monoclonal antibodies mean better results?
Analysis of: Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers | www.pipelinereview.com
Author: GLG Member Program Contributor
The use of immunoconjugates in the development of monoclonal antibodies has been long tested with toxins but not with pro-drugs
Previous Page : 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Next191 to 200 of 782

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617